Latest Breaking News On - Judith klimovsky - Page 1 : comparemela.com

Genmab A/S: Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Preliminary analysis of data from the EPCORE NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with rituximab-lenalidomide

United statesJudith klimovskyHematol hemoterAsia pacificJoshua brodyDavid freundelAndrew carlsenDrug administrationLymphoma research foundationLeukemia lymphoma societyGenmab us incAmerican society of clinical oncologyGlobal communications corporate affairsData from the observational national lymphocare studyExchange commissionAbbvie biotechnology ltd

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

02.06.2024 - Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of .

United statesJudith klimovskyAsia pacificHematol hemoterJoshua brodyLymphoma research foundationDrug administrationGenmab us incData from the observational national lymphocare studyLeukemia lymphoma societyExchange commissionAbbvie biotechnology ltdExecutive vice presidentChief development officerMount sinai hess centerPriority review

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesAsia pacificJoshua brodyJudith klimovskyHematol hemoterAmerican society of clinical oncologyGenmab us incDrug administrationData from the observational national lymphocare studyLymphoma research foundationAbbvie biotechnology ltdExchange commissionLeukemia lymphoma societyClinical oncologyAnnual meetingExecutive vice president

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic.

United statesAsia pacificAndrew carlsenFosun pharmaDavid freundelJudith klimovskyGlobenewswire incAmerican cancer societyAmerican society of clinical oncologyExchange commissionRoche groupClinical oncologyAnnual meetingExecutive vice presidentChief development officerChief medical officer

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with.

United statesJudith klimovskyFosun pharmaDavid freundelAndrew carlsenAsia pacificExchange commissionAmerican society of clinical oncologyAmerican cancer societyRoche groupClinical oncologyAnnual meetingExecutive vice presidentChief development officerChief medical officerNon small cell lung cancer